Zambon is a leading Italian family company that has operated for 109 years in the pharmaceutical and fine-chemical industry. Founded in Vicenza in 1906, today the Group operates directly in 84 countries with 19 operating subsidiaries in Europe, South America and Asia and more than 2,800 employees. Zambon has also facilities in Italy (Vicenza, Lonigo), Switzerland, France, Brazil and China. Zambon primarily operates in three strategic areas: respiratory, pain and womenÍs health. In these sectors, its business covers the entire value chain. The Group is particularly focusing on strengthening the respiratory area with the treatment of severe diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), with the recent acquisition of Profile Pharma from Philips. Zambon entered also into a new important therapeutic area, the Central Nervous System (CNS), with an innovative molecule for the treatment of Parkinson's disease. CNS and the Respiratory Business are the two main drivers of the companyÍs development strategy. Zambon is characterised by a strong identity and integrated organisational structure. Zambon Company is the industrial holding company, made up of Zach, Zambon Chemicals, which operates in the production of active ingredients and intermediates in three business areas: generic, custom and Zambon branded products. Other parts of the Group are: Zambon SpA global pharmaceutical business and Z-Cube, the Corporate Venture that supports the validation of drug delivery technologies and medical devices. ZCube has also developed a strong relationship with the International scientific community and has renovated a company history in the research and innovation field thanks to Open Zone, a scientific campus for the exchange of knowledge, research and innovation. In addition Zo_ Foundation, was born with the aim of spreading a healthÍs culture enhancing a good communication both on the academic field and institutional field.